Therapeutic Response

PD-L1 >= 5% status confers therapeutic sensitivity to Atezolizumab in patients with Bladder Urothelial Carcinoma.

Statements

Source and description
Tecentriq (atezolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are considered cisplatin ineligible, and whose tumors have PD-L1 expression >= 5%.